We studied the effects of ANG II on extracellular signal-regulated kinase (ERK)1/2 phosphorylation in rat pituitary cells. ANG II increased ERK phosphorylation in a time-and concentration-dependent way. Maximum effect was obtained at 5 min at a concentration of 10-100 nM. The effect of 100 nM ANG II was blocked by the AT1 antagonist DUP-753, by the phospholipase C (PLC) inhibitor U-73122, and by the MAPK kinase (MEK) antagonist PD-98059. The ANG II-induced increase in phosphorylated (p)ERK was insensitive to pertussis toxin blockade and PKC depletion or inhibition. The effect was also abrogated by chelating intracellular calcium with BAPTA-AM or TMB-8 by depleting intracellular calcium stores with a 30-min pretreatment with EGTA and by pretreatment with herbimycin A and PP1, two c-Src tyrosine kinase inhibitors. It was attenuated by AG-1478, an inhibitor of epidermal growth factor receptor (EGFR) activation. Therefore, in the rat pituitary, the increase of pERK is a Gq-and PLCdependent process, which involves an increase in intracellular calcium and activation of a c-Src tyrosine kinase, transactivation of the EGFR, and the activation of MEK. Finally, the response of ERK activation by ANG II is altered in hyperplastic pituitary cells, in which calcium mobilization evoked by ANG II is also modified. calcium; phospholipase C; protein kinase C; estrogen; mitogen-activated protein kinase; epidermal growth factor receptor IT HAS BEEN DESCRIBED that all the components of the renin-angiotensin II system (RAS) are present in the pituitary, where angiotensin II (ANG II) is produced locally (5) and principally synthesized in gonadotropes (6). Two ANG II receptor subtypes, AT 1 and AT 2 , first distinguished on a pharmacological basis, have been identified by expression cloning from various species, and the main biological functions exerted by ANG II are mediated by the AT 1 receptor subtype.
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calcium; phospholipase C; protein kinase C; estrogen; mitogen-activated protein kinase; epidermal growth factor receptor IT HAS BEEN DESCRIBED that all the components of the renin-angiotensin II system (RAS) are present in the pituitary, where angiotensin II (ANG II) is produced locally (5) and principally synthesized in gonadotropes (6) . Two ANG II receptor subtypes, AT 1 and AT 2 , first distinguished on a pharmacological basis, have been identified by expression cloning from various species, and the main biological functions exerted by ANG II are mediated by the AT 1 receptor subtype. The rat anterior pituitary predominantly expresses the AT 1B isoform of the AT 1 receptor (18, 21, 33) , with a low expression of the AT 1A isoform and the AT 2 receptor subtype (33, 36) . AT 1B receptors are found mainly in lactotropes and to a lesser extent in corticotropes and thyrotropes (21) .
AT 1 receptors belong to the family of G proteincoupled receptors (GPCR). In the rat pituitary, activation of AT 1B receptors coupled to a G q/11 protein increases phospholipase C-␤ (PLC␤) activity, resulting in inositol 1,4,5-triphosphate (IP 3 ) and diacylglycerol (DAG) formation, followed by a biphasic increase in intracellular calcium concentration ([Ca 2ϩ ] i ). Coupling of the AT 1 receptor to a G i protein has also been described (11, 29) . In both central and peripheral cells, AT 1 receptors also mediate ANG II-stimulated increase in the expression of protooncogenes (9, 11, 28, 38, 45) and stimulation of the JAK/STAT pathway, which has originally been associated with growth factors and cytokines. In addition, mitogen-activated protein kinases (MAPKs), which are critical components in cellular processes such as growth, differentiation, and apoptosis, are activated by ANG II binding to AT 1 receptors in various cell types (9, 16, 27, 42) .
MAPKs, also termed extracellular signal-regulated kinases or ERKs, belong to a family of protein serine/ threonine kinases that are believed to function as integrators of mitogenic signals originating from several distinct classes of cell surface receptors, mainly receptor tyrosine kinases (RTKs) but also GPCRs. In response to an extracellular stimulus, their activated forms, p42 MAPK (pERK2) and p44 MAPK (pERK1), are generated by phosphorylation of specific threonine and tyrosine residues catalyzed by an MAPK kinase family member, also known as MAPKK or MEK. The cascade from growth factor RTKs to ERK has been elucidated (23); however, the ERK activation pathway originating from GPCRs is beginning to unfold. It has been described that ANG II stimulates ERKs in hepatic cells (35) , neurons (16) , vascular smooth muscle cells (9) , cardiac fibroblasts (27) , bovine adrenal glomerulosa cells (42) , and several other cell types, but no description of activation of ERKs by ANG II in pituitary cells has been documented.
We have therefore investigated the effects of ANG II on ERK activation, as well as the signal transduction cascades involved, in rat pituitary cells. Furthermore, because we have previously described that ANG II response is greatly modified in estrogen-induced pituitary hyperplasia (7, 12, 13) , we compared results in control and in hyperplastic pituitary cells.
MATERIALS AND METHODS
Materials. DUP-753 was a generous gift from DuPont Merck Pharmaceutical (Wilmington, DE), and the AT 2 antagonist PD-123319 was a gift from Parke-Davis (Ann Arbor, MI). Chelerytrine was from Alomone Labs (Jerusalem, Israel), and tyrphostin AG-1478 and PP1 were from Biomol Research Laboratories (Plymouth Meeting, PA). All other chemicals were purchased from Sigma (St. Louis, MO) unless otherwise specified.
Animals. Female regularly cycling 60-day-old SpragueDawley rats were housed in an air-conditioned room with lights on at 0700 and off at 1900. They had free access to laboratory chow and tap water. Rats were maintained in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Rats in diestrus were used as the control group.
Pituitary hyperplasia was developed by subcutaneous implantation of a 20-mg diethylstilbestrol pellet; rats were killed after 8 wk of treatment.
Cell culture. Cell dispersion and culture were performed as previously described (13) . After 4 days in culture, cells were washed twice with DMEM-F12 [Dulbecco's modified Eagle's medium with F-12 Nutrient Mixture (GIBCO), supplemented with 1% BSA, 2 mM glutamine, 25,000 U/l nystatin, and 25 ng/l gentamicin] to remove all traces of serum. Fresh medium (without serum and with the stimuli that required a 24-h preincubation when necessary) was added, and cells were incubated at 37°C for 24 h before stimulation with appropriate drugs.
Immunoblotting. Pituitary cells (500,000 cells/well) were then stimulated with agonists at 37°C in serum-free DMEM for the indicated times. The reaction was terminated by the replacement of the medium with 60 l of 62.5 mM Tris ⅐ HCl (pH 6.8), 2% SDS, 10% glycerol, 50 mM dithiothreitol, and 0.1% bromophenol blue. After 5 s of sonication, samples were boiled for 5 min at 95°C, and 20 l were subjected to SDSpolyacrylamide gel electrophoresis and electroblotted onto a nitrocellulose membrane (Bio-Rad, Buenos Aires, Argentina). Membranes were probed with mouse polyclonal phosphospecific ERK antibody (1:1,000, Santa Cruz Biotechnologies, Santa Cruz, CA). After incubation with secondary antimouse antibody conjugated with horseradish peroxidase (1: 2,500, Santa Cruz Biotechnologies), immunoreactive proteins were detected by enhanced chemiluminescence. Membranes were stripped in 62.5 mM Tris, 2% SDS, and 100 mM mercaptoethanol, pH 6.7, for 40 min at 50°C and then incubated with rabbit polyclonal anti-ERK1 antibody (1:1,200, Santa Cruz Biotechnologies) and then with antirabbit antibody conjugated with horseradish peroxidase (Santa Cruz Biotechnologies) and revealed as described. Bands were quantitated using the ImageQuant software.
Intracellular calcium measurement. Measurements were made as previously described (14) .
Statistical analysis. Results are expressed as means Ϯ SE. pERK1 and pERK2 band intensity was normalized in all cases to total ERK1, and the pERK/ERK1 ratio is presented. For those figures that include pretreatment and acute treatment, two-way ANOVA for repeated measures for the effects of pretreatment and treatment was performed. In all cases, if F of interaction was found significant, individual means were compared by Tukey's honestly significant difference or Fisher's protected least significant difference tests; if it was not significant, groups of means were analyzed by the same tests. Time course and concentration dependence of ERK phosphorylation were analyzed by one-way ANOVA for repeated measures. P Ͻ 0.05 was considered significant.
RESULTS

ANG II type 1 receptor stimulation leads to ERK phosphorylation in pituitary cells.
In cultured anterior pituitary cells, ANG II (100 nM) induced maximal ERK phosphorylation at 5 min, and the response declined at 10-15 min (Fig. 1A) . ERK phosphorylation was dependent on the concentration of the agonist (Fig. 1B) . Increased phosphorylation was detectable at 0.1 nM, half-maximal at ϳ1.6 nM, and maximal at 10-100 nM. Therefore, subsequent assays on ANG II-induced ERK phosphorylation were performed with 100 nM ANG II stimulation for 5 min. To determine which receptor subtype mediates pERK increase, pituitary cells were pretreated for 30 min with either the AT 1 antagonist DUP-753 (losartan) or the AT 2 antagonist PD-123319. ERK phosphorylation by ANG II was abolished by 10 M DUP-753, whereas the same concentration of PD-123319 did not alter the effect of the octapeptide ( Fig.  2A) , indicating that ANG II-induced ERK phosphorylation is mediated mainly by the AT 1 receptor in pituitary cells.
Pituitary cells also express RTKs linked to growth factors. Thus addition of epidermal growth factor (EGF; 10 ng/ml) for 5 min caused a marked increase in ERK1/2 phosphorylation (Fig. 2B) . Moreover, the MEK1 kinase inhibitor PD-98059 (50 M) abolished ERK phosphorylation induced by both ANG II (100 nM) and EGF (P ϭ 0.0041 and 0.016, respectively; Fig. 2B ).
ANG II-induced ERK phosphorylation requires PLC activation through a pertussis toxin-insensitive G protein.
It has been reported that AT 1 receptors can be coupled to either G q or G i proteins, which activate PLC␤ or inhibit adenylate cyclase, respectively. To determine which G protein-mediated signaling is involved in ERK phosphorylation by ANG II in pituitary cells, the effects of pretreatment with pertussis toxin (PTX) and with U-73122, a specific PLC␤ inhibitor, were studied. Pretreatment with PTX (150 ng/ml) for 24 h had no effect on the response evoked by ANG II [ Fig. 3A ; effect of ANG II vs. basal after buffer or PTX pretreatment: P ϭ 0.0023, F of interaction ϭ 0.089 not significant (NS)]. In contrast, pretreatment with 10 M U-73122 reduced ANG II-induced ERK phosphorylation (effect of ANG II vs. basal after buffer or U-73122 pretreatment: P ϭ 0.0044 and 0.15, respectively; Fig.  3B ). U-73122 (10 M) induced a significant increase in [Ca 2ϩ ] i , evidenced 5 s after the stimulus, with a maximum response at 45 s (Fig. 3C) . When 100 nM ANG II was added 7 min after U-73122, there was no response to ANG II (compared with buffer-pretreated cells). U-73122 also blocked the K ϩ (25 mM)-induced [Ca 2ϩ ] i increase.
Role of PKC in ANG II-induced ERK phosphorylation.
In cultured pituitary cells, PLC␤ activation by ANG II leads to production of two second messengers, IP 3 and DAG, which induce the release of Ca 2ϩ from intracellular stores and PKC activation, respectively. Because PKC activation by a phorbol ester has been reported to stimulate MAPK in other cells (9), we examined whether phorbol ester-sensitive PKC is essential for ANG II-induced ERK phosphorylation in pituitary cells. Depletion of PKC by a 24-h pretreatment with 1 M phorbol 12-myristate 13-acetate (PMA 24) moderately decreased basal ERK phosphorylation (P ϭ 0.32) and completely inhibited ERK phosphorylation induced by a 10-min stimulation with 1 M PMA (PMA 10; Fig. 4A ), confirming the completeness of the PKC depletion. However, ANG II-induced ERK phosphorylation was not inhibited by PMA 24 pretreatment (P ϭ 0.027 and 0.0027 with and without pretreatment, respectively), suggesting a dominant role of a PKCindependent mechanism in ANG II-induced ERK phosphorylation in pituitary cells. This was confirmed using the specific PKC inhibitor chelerythrine (15) . A (Fig. 5, A and B) . Both chelators also reduced the pERK increase induced by the octapeptide ( If EGTA pretreatment lasted for 10 min (or more), basal [Ca 2ϩ ] i also decreased and 100 nM ANG II could not evoke a consistent Ca 2ϩ response (Fig. 6B) , indicating that intracellular Ca 2ϩ stores had been depleted. Consequently, 100 nM ANG II failed to increase ERK phosphorylation (effect of ANG II vs. basal, with buffer or 30-min EGTA pretreatment: P ϭ 0.0021 and 0.80, respectively; Fig. 6C) .
Role of Src-tyrosine kinase and EGFR activation on ERK phosphorylation. ANG II has been shown to cause a rapid increase in tyrosine phosphorylation of multiple cellular proteins before ERK activation in different systems. We therefore examined the role of c-Src kinases in ANG II-induced ERK activation.
Herbimycin A, a c-Src tyrosine kinase inhibitor, reduced the phosphorylation of ERK1/2 induced by ANG II (Fig. 7A) (effect of ANG II vs. basal in buffer and in herbimycin A-pretreated cells: P ϭ 0.016 and 0.56, respectively). To confirm this effect, we tested a more selective inhibitor of the Src-family tyrosine kinases, PP1 (10 M). In this case, a complete inhibition of ANG II-induced ERK1/2 phosphorylation was evidenced It is well established that transactivation of the EGFR contributes to GPCR-mediated ERK1/2 activation in certain cell types. Pituitary cells express EGFR, and, as we showed, EGF stimulation caused a marked increase in ERK1/2 phosphorylation. To examine the involvement of the EGFR in ANG II-induced ERK1/2 activation, cells were pretreated with the selective EGFR kinase inhibitor AG-1478. AG-1478 at 400 nM attenuated ANG II (100 nM)-induced ERK1/2 phosphorylation (Fig. 7B) (effect of ANG II in buffer-pretreated compared with AG-1478-pretreated cells: P ϭ 0.010), indicating its dependence on transactivation of the EGFR. AG-1478 at 400 nM blocked EGF (10 ng/ ml)-induced ERK1/2 phosphorylation (data not shown).
ANG II-induced ERK phosphorylation and [Ca 2ϩ ] i mobilization in cells from hyperplastic pituitaries.
In cells from estrogen-induced pituitary hyperplasia, the profile of pERK increase in response to ANG II (100 nM) was different from that of control cells (Fig. 8A) . Maximum increase was lower and less abrupt. The increase was evidenced at 5 min, peaked at 10 min, and was still significant at 15 min. In correlation, [Ca 2ϩ ] i mobilization evoked by ANG II (100 nM) in hyperplastic cells did not present an early peak phase but rather a prolonged plateau phase (Fig. 8B) . Signaling mechanisms in ANG II-induced ERK phosphorylation in pituitary cells exhibited similarities and differences with endogenously expressed or transfected AT 1 receptors in diverse cell types. Therefore, ERK activation by ANG II may be a cell-specific phenomenon, and discrepant results may be related to different amounts of expressed receptors or differential cell expression of elements involved in the mechanism of agonist-induced ERK activation.
In pituitary cells, the ANG II-induced increase in pERK was a concentration-dependent process that reached an apparent maximum after 5 min of stimulation with 10-100 nM of the octapeptide. The estimated half-maximal effective concentration (EC 50 , 1.59 nM) was in the range of the K d for the AT 1 receptor in the pituitary (3). Fifteen minutes after ANG II stimulation, ERK phosphorylation returned to basal levels. This pattern of response is similar to that found in VSMCs (9) and cardiac fibroblasts (27) . On the other hand, in bovine adrenal glomerulosa (BAG) cells, the response returned to basal levels at 60 min, and maximal phosphorylation was elicited by concentrations as low as 500 pM (42) . Moreover, in CHO fibroblasts overexpressing the rat AT 1A receptor, ANG II induced a biphasic elevation of ERK activity (44) .
The effect of ANG II was blocked by the AT 1 receptor antagonist losartan and not by the AT 2 antagonist PD-123319, indicating that ANG II-induced ERK phosphorylation is mediated by the AT 1 receptor in pituitary cells. Similar results have been described in most tissues studied, with the exception of neonatal neurons, in which AT 1 and AT 2 receptors have opposite actions on ERK activation (16) .
The cloned AT 1 receptor can be coupled to either G q or G i proteins (29) . ANG II-induced ERK phosphorylation was PTX insensitive in pituitary cells, and it was suppressed by the PLC␤ inhibitor U-73122. Taken together, these observations indicate that, in pituitary cells, the AT 1 receptor transduces its signal through a PTX-insensitive G q protein as it has been described in VSMCs (9, 42) , rather than through a G i protein as was proposed for hepatic C9 cells (35) . U-73122 also prevented an ANG II-induced spike in [Ca 2ϩ ] i , consistent with its role as a specific inhibitor of PLC, but surprisingly it acutely increased [Ca 2ϩ ] i and prevented the depolarization-induced rise in [Ca 2ϩ ] i . It has been described that U-73122 can directly activate ion channels and can itself promote the release of Ca 2ϩ from intracellular stores (24) through inhibition of the internal Ca 2ϩ pump in hepatic microsomes (4) . Therefore, these results would caution that U-73122 may not be selective at concentrations required for maximal blockade of PLC and that the selectivity of U-73122 may be dependent on cell type.
It has been proposed that a G q protein-coupled receptor can activate ERK through PKC activation (43) . PKC is known to activate ERK, presumably by inducing the phosphorylation of the EGFR and subsequent activation of Ras/Raf/MEK/ERK (35) . Because the present study showed that ANG II-induced ERK phosphorylation was probably a PLC-dependent process and the octapeptide has been shown to stimulate PKC activity in pituitary cells through PLC-mediated DAG production (37), we tested the hypothesis that ANG II could activate ERK pathways by activated PKC. The present results clearly showed that PKC depletion by prolonged PMA treatment or pretreatment with the specific PKC inhibitor chelerythrine had no effect on ERK phosphorylation by ANG II. Therefore, our data point to the dominant role of a PKC-independent pathway in ANG II-induced ERK activation in pituitary cells. This is in contrast to results obtained in VSMCs (25) , BAG cells (42), AT 1 -expressing CHO cells (1), or hepatic cells (35) , in which ANG II-induced ERK activation was dependent on PKC. Nevertheless, other studies indicate that calcium signaling, rather than PKC, plays a critical role in ERK activation induced by the octapeptide (9, 27, 31, 46 (35) .
To determine whether tyrosine kinase activity was required for ERK phosphorylation in response to ANG II, cells were pretreated with herbimycin A, an inhibitor of Src family tyrosine kinases, or with PP1, a more selective c-Src tyrosine kinase inhibitor. Herbimycin A lowered, and PP1 inhibited, the increase of pERK in response to ANG II. This indicates that a c-Src tyrosine kinase is involved in ANG II-induced ERK phosphorylation even though other component(s) might participate in this mechanism. These results are consistent with the finding that, in VSMCs from c-Src-deficient transgenic mice, a decrease in ANG II-induced ERK activity was described (17) . Several studies emphasize the importance of c-Src in ANG II-stimulated ERK activity in VSMCs (9) and cardiac cells (27) . However, other groups reported that herbimycin A failed to block ANG II-induced increase in ERK activity in vascular and aortic smooth muscle cells (20, 39) and in an opossum kidney cell line (41) .
There is now abundant evidence for the frequent involvement of EGFR transactivation in GPCR-and particularly in ANG II-mediated ERK activation (22, 32) , and it has been suggested that c-Src activation precedes EGFR transactivation. In pituitary cells, inhibition of EGFR phosphorylation with AG-1478 attenuated ERK1/2 phosphorylation, suggesting that this may be a common mechanism shared by several GPCRs coupled to G q , such as AT 1 . Similar involvement of EGFR transactivation in the effect of ANG II has been described in VSMCs (8, 10) , hepatic C9 cells (35) , and cardiac fibroblasts (26) . Nevertheless, incomplete inhibition of ANG II-induced ERK activation by AG-1478 was observed in our experiments, as was described in VSMCs (10) . This may indicate that the activation induced by ANG II is not exclusively mediated by the AG-1478-sensitive pathway in our tissue.
The present study demonstrates that, in pituitary cells, ANG II-induced ERK phosphorylation is dominantly mediated by a G q protein-coupled, PLC␤-and Ca 2ϩ -dependent mechanism. The signaling response to ANG II also involves a nonreceptor tyrosine kinase, the c-Src kinase, and transactivation of the EGFR. When other results in the literature are considered, it is apparent that the pathways leading to ERK phosphorylation from the AT 1 receptor, and the role played by PKC, Ca 2ϩ , and tyrosine kinases in these pathways, vary considerably among different cell types, consistent with multiple pathways converging on ERK. The mechanism used by a given receptor to stimulate ERK is likely to be dependent on the subtype of G protein and downstream components expressed by a given cell type. Therefore, the quest for agonist-induced ERK activation is orchestrated and shaped in any particular cell by a myriad of components expressed in a cell-, tissue-, and time-dependent fashion. Under this scenario, it might be possible that additional cell-and tissue-specific signaling molecules may contribute synergistically to ANG II-specific component(s) in the ERK activation process.
Finally, we described an altered activation pattern of ERK in cells from estrogen-induced pituitary hyperplasia. In a previous work (12), we showed that estrogen alters calcium influx and mobilization in response to ANG II in pituitary cells. Our present results indicate that, in control pituitary cells, the effect of ANG II on ERK phosphorylation was dependent on the elevation of [Ca 2ϩ ] i . Consistent with these results, we found that, in hyperplastic cells, ERK activation was altered in correlation with an altered increase in [Ca 2ϩ ] i in response to ANG II. In VSMCs, it has also been demonstrated that estrogen attenuates AT 1 receptor-mediated ERK activation and that estrogen antagonizes the effect of the AT 1 receptor via the activation and induction of phosphatases through nongenomic as well as genomic signaling (40) . These results may be of paramount importance if we consider that two of the most highly recognized factors implicated in the pathogenesis of hypertension, atherosclerosis, congestive heart failure, and associated cardiovascular disease are the RAS and estrogen and that a major effect of estrogen on these diseases results from its influence on the RAS.
